drug
amfetamine ER
Marketedupdated 3mo agoby Tris Pharma Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 6Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for attention deficit hyperactivity disorder and 3 investigational indications.
indications
investigational
Obesity
all catalysts(17)
approval · 17
Oct 19, 2015
approval
$TRAW
DYANAVEL XR (AMPHETAMINE) — FDA approval
amfetamine ER
→
Jan 4, 2017
approval
$TRAW
DYANAVEL XR (AMPHETAMINE) — FDA approval
amfetamine ER
→
May 12, 2017
approval
$TRAW
DYANAVEL XR (AMPHETAMINE) — FDA approval
amfetamine ER
→
Feb 5, 2019
approval
$TRAW
DYANAVEL XR (AMPHETAMINE) — FDA approval
amfetamine ER
→
Aug 5, 2019
approval
AMPHETAMINE SULFATE — FDA approval
amfetamine ER
→
Oct 27, 2020
approval
AMPHETAMINE SULFATE — FDA approval
amfetamine ER
→
Feb 10, 2022
approval
AMPHETAMINE SULFATE — FDA approval
amfetamine ER
→
Feb 25, 2022
approval
$TRAW
DYANAVEL XR (AMPHETAMINE) — FDA approval
amfetamine ER
→
Feb 25, 2022
approval
AMPHETAMINE SULFATE — FDA approval
amfetamine ER
→
Feb 25, 2022
approval
AMPHETAMINE SULFATE — FDA approval
amfetamine ER
→
Jun 1, 2022
approval
$TRAW
DYANAVEL XR (AMPHETAMINE) — FDA approval
amfetamine ER
→
Oct 13, 2023
approval
AMPHETAMINE SULFATE — FDA approval
amfetamine ER
→
Oct 13, 2023
approval
$TRAW
DYANAVEL XR (AMPHETAMINE) — FDA approval
amfetamine ER
→
Oct 17, 2023
approval
AMPHETAMINE SULFATE — FDA approval
amfetamine ER
→
Sep 23, 2025
approval
$TRAW
DYANAVEL XR (AMPHETAMINE) — FDA approval
amfetamine ER
→
Sep 26, 2025
approval
AMPHETAMINE SULFATE — FDA approval
amfetamine ER
→
Sep 26, 2025
approval
AMPHETAMINE SULFATE — FDA approval
amfetamine ER
→
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 15, 2027
216 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (69)
- Feb 11, 2040method-of-use (U-3538)US 12458592
- Feb 11, 2040method-of-use (U-3538)US 12458592
- Feb 11, 2040method-of-use (U-3538)US 12458592
- Sep 24, 2038formulationUS 11590081
- Sep 24, 2038formulationUS 11590081
- Sep 24, 2038formulationUS 11590081
- Mar 10, 2037formulationUS 10441554
- Mar 10, 2037formulationUS 10441554
- Mar 10, 2037formulationUS 10441554
- Mar 10, 2037formulationUS 10441554
- Mar 10, 2037formulationUS 10441554
- Mar 10, 2037formulationUS 11160772
- Mar 10, 2037formulationUS 11160772
- Mar 10, 2037formulationUS 11160772
- Mar 10, 2037formulationUS 11160772
- Mar 10, 2037formulationUS 11160772
- Mar 10, 2037method-of-use (U-3299)US 11896562
- Mar 10, 2037method-of-use (U-3299)US 11896562
- Mar 10, 2037method-of-use (U-3299)US 11896562
- Mar 10, 2037method-of-use (U-3299)US 11896562
- Sep 7, 2036formulationUS 11590228
- Jun 28, 2032formulationUS 8709491
- Jun 28, 2032formulationUS 8709491
- Jun 28, 2032formulationUS 8709491
- Jun 28, 2032formulationUS 8709491
- Jun 28, 2032formulationUS 8709491
- Jun 28, 2032formulationUS 8709491
- Jun 28, 2032formulationUS 8709491
- Jun 28, 2032formulationUS 9017731
- Jun 28, 2032formulationUS 9017731
- Jun 28, 2032formulationUS 9017731
- Jun 28, 2032formulationUS 9017731
- Jun 28, 2032formulationUS 9017731
- Jun 28, 2032formulationUS 9017731
- Jun 28, 2032formulationUS 9017731
- Jun 28, 2032formulationUS 9265737
- Jun 28, 2032formulationUS 9265737
- Jun 28, 2032formulationUS 9265737
- Jun 28, 2032formulationUS 9265737
- Jun 28, 2032formulationUS 9265737
- Jun 28, 2032formulationUS 9265737
- Jun 28, 2032formulationUS 9265737
- Jun 28, 2032formulationUS 9839619
- Jun 28, 2032formulationUS 9839619
- Jun 28, 2032formulationUS 9839619
- Jun 28, 2032formulationUS 9839619
- Jun 28, 2032formulationUS 9839619
- Jun 28, 2032formulationUS 9839619
- Mar 29, 2029formulationUS 80626672.6y
- Mar 15, 2027formulationUS 10086087216d
- Mar 15, 2027formulationUS 8337890216d
- Mar 15, 2027formulationUS 8337890216d
- Mar 15, 2027formulationUS 8337890216d
- Mar 15, 2027formulationUS 8597684216d
- Mar 15, 2027formulationUS 8747902216d
- Mar 15, 2027formulationUS 8747902216d
- Mar 15, 2027formulationUS 8747902216d
- Mar 15, 2027formulationUS 8747902216d
- Mar 15, 2027formulationUS 8883217216d
- Mar 15, 2027formulationUS 9675703216d
- Mar 15, 2027formulationUS 9675704216d
- Mar 15, 2027formulationUS 9675704216d
- Mar 15, 2027formulationUS 9675704216d
- Apr 9, 2026formulationUS 8840924
- Apr 9, 2026formulationUS 8840924
- Apr 9, 2026formulationUS 8840924
- Apr 9, 2026formulationUS 8840924
- Apr 9, 2026formulationUS 8840924
- Apr 9, 2026formulationUS 8840924
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 55m ago
Found something off?
comments(0)
5-min edit window · permanent after that